The full gene sequencing for BRCA1/BRCA2 mutation
About 5–10% of patients with breast and/or ovarian cancer carry a mutation in the BRCA1/BRCA2 genes. For those that carry a mutation in one of these two genes, the lifetime risk of developing related cancer is 50–85%.
Find your BRCA 1/BRCA 2 genetic test
Breast cancer testing for an early cancer diagnosis
The critical goal is to detect cancer early and to give you the opportunity to maximize health outcomes for your patients. Genetic testing for the BRCA1 and BRCA2 genes at CENTOGENE enables you to identify patients with an increased risk of developing breast cancer and, depending on the gene, additional tumors. Patient-tailored screening programs, preventive measures and proactive treatment are possible for patients of a high-risk group. Early diagnosis can mean a better overall prognosis through a choice of surgical and non-surgical treatment options.
Over the past years we have analyzed thousands of patients' BRCA samples from all over the world. This medical expertise, combined with the constant optimization of our internal processes and implementation of new diagnostic techniques, gives us the opportunity to support you with an attractive diagnostic offer for full gene sequencing of the BRCA1 and BRCA2 genes.
For patients who are BRCA1/BRCA2 negative, we offer alternative gene panels including additional genes linked to hereditary breast and/or ovarian cancer.
When to test for BRCA1/BRCA2 mutations
A BRCA1 or BRCA2 testing is recommended when a patients' personal or family history shows any of the following:
- Breast cancer diagnosed at 50 or younger*
- Ovarian cancer at any age
- Multiple breast cancers, bilateral or ipsilateral*
- Both breast and ovarian cancer
- Male breast cancer*
- Triple-negative (estrogen receptor negative, progesterone receptor negative and HER2/neu negative) breast cancer
- Pancreatic cancer with breast or ovarian cancer in the same individual or on the same side of the family
- Two or more relatives with breast cancer, one under age 50
- Three or more relatives with breast cancer at any age
- A previously identified BRCA1 or BRCA2 mutation in the family*
*according to the Evidence-Based Cancer Guidelines, National Comprehensive Cancer Network (NCCN).
Scientific Articles on BRCA 1/2
Next-Generation Sequencing of the BRCA1 and BRCA2 Genes for the Genetic Diagnostics of Hereditary Breast and/or Ovarian Cancer
We explored a more efficient genetic screening strategy based on next-generation sequencing of the BRCA1 and BRCA2 genes in 210 hereditary breast and/or ovarian cancer patients.
Ordering information – all important data at one glance
|Gene test:||BRCA1/BRCA2 panel|
|Gene name:||BRCA1, BRCA2|
|Sample requirements:||2µg DNA or 2 mL EDTA blood or 1 filter card|
*Hotspots for BRCA1: c.185delAG, c.300T>G, c.322-11T>G, c.339C>T, c.433A>G, c.835A>G, c.1186A>G, c.1186delA, c.1201del11, c.1235G>A, c.1675delA, c.1740C>T, c.1806C>T, c.2457C>T, c.2524delTG, c.2800delAA, c.2841G>T, c.3172ins5 TGAGA, c.3232A>G, c.3600del11, c.3604delA, c.3780G>T, c.3819del5 GTAAA, c.3829delT, c.3832C>T, c.3867G>T, c.3875del4 GTCT, c.3880delAG, c.4154delA, c.4158A>G, c.4808C>G, c.4956A>G, c.5002T>C, c.5149del4 CTAA, c.5214C>T, c.5256delG, c,5370C>T, c.5382insC, c.5396+1G>A, c.433delT, c.5465G>A, c.5611delC, c.5622C>T.
*Hotspots for BRCA2: c.353A>G (C.125A>G), c.862delAG, c.999del5, c.1514T>C, c.1792A>G, c.2192C>G, c.3063del4, c.4075delGT, c.4088insA, c.5445del4, c.5445del5, c.5445del7, c.5445del8, c.5645C>A, c.7397C>T, c.7469T>C, c.5873C>G, c.5873C>A, c.5946delT, c.6275_6276delTT, c.6323G>A, c.6495delGCAinsC, c.6503delTT, c.6633del5, c.7049G>T, c.7489C>T, c.7772C>T, c.8168A>C, c.8182G>A, c.8297delC, c.8567A>C, c.8851G>A, c.9038C>T, c.9097dupA, c.9285C>G, c.9292T>C, c.9371A>T, c.9610C>T, c.10152C>G, c.10234A>G, c.10462A>G, c.1310_1313delAAGA.